Press Release / Mar 17, 2021
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Make your drug soluble with Dispersome® technology. Dispersome® is a solubility enhancement technology that relies on an innovative and naturally occurring excipient to develop amorphous solid dispersions with high drug loading and high bioavailability.
Commitment to partnership and joint innovation for cell and gene therapies